Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the appointment of…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$SF #Blade–Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$SF #Blade–Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$SF #Blade–Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics…
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases,…
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases,…
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases,…